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Cardiac Resynchronization in Women February 15, 2011:813–20Cardiac Resynchronization Therapy Is More Effective in Women Than in Men
The MADIT-CRT (Multicenter Automatic Defibrillator
Implantation Trial With Cardiac Resynchronization Therapy) Trial
Objectives The purpose of this study was to investigate the factors related to sex-specific outcomes for death and heart fail-
ure events in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchroniza-
tion Therapy) trial.
Background In the MADIT-CRT trial, women seemed to achieve a better result from resynchronization therapy than men.
Methods All 1,820 patients (453 female and 1,367 male) enrolled in the MADIT-CRT trial were included in this sex-
specific outcome analysis that compared the effect of cardiac resynchronization therapy with defibrillator
(CRT-D) relative to implanted cardioverter-defibrillator (ICD) on death or heart failure (whichever came first),
heart failure only, and death at any time.
Results Female patients were more likely to have nonischemic cardiomyopathy and left bundle branch block and less
likely to have renal dysfunction than male patients. Overall, female patients had a better result from CRT-D ther-
apy than male patients, with a significant 69% reduction in death or heart failure (hazard ratio: 0.31, p  0.001)
and 70% reduction in heart failure alone (hazard ratio: 0.30, p  0.001). Women had a significant 72% reduc-
tion in all-cause mortality in the total population (hazard ratio: 0.28, p  0.02) and significant 82% and 78%
reductions in mortality in those with QRS 150 ms and with left bundle branch block conduction disturbance,
respectively, with sex-by-treatment interactions for mortality reduction significant at p  0.05 in each of these 3
patient groups. These beneficial CRT-D effects among women were associated with consistently greater echocar-
diographic evidence of reverse cardiac remodeling in women than in men.
Conclusions Women in the MADIT-CRT trial obtained significantly greater reductions in death or heart failure (whichever
came first), heart failure alone, and all-cause mortality with CRT-D therapy than men, with consistently greater
echocardiographic evidence of reverse cardiac remodeling in women than in men. (Multicenter Automatic Defi-
brillator Implantation Trial With Cardiac Resynchronization Therapy [MADIT-CRT]; NCT00180271). (J Am Coll
Cardiol 2011;57:813–20) © 2011 by the American College of Cardiology FoundationCardiac resynchronization therapy with defibrillator
(CRT-D) is an approved treatment for patients with ad-
vanced stages of heart failure in the setting of widened QRS,
and this therapy is associated with reduction in symptoms,
improvement in functional capacity, and decrease in hospi-
talization and mortality (1). The recently reported random-
ized MADIT-CRT (Multicenter Automatic Defibrillator
Implantation Trial With Cardiac Resynchronization Ther-
apy) trial demonstrated that CRT-D treated patients with
New York Heart Association (NYHA) functional class I
and II heart failure symptoms, left ventricular ejection
fraction (LVEF) 0.30 and QRS 130 ms had a 34%
reduction in the risk of heart failure or death, whichever
came first, when compared with patients treated with an
implantable cardioverter-defibrillator (ICD) (2). In this
substudy from the MADIT-CRT trial, we report the
sex-specific outcomes with CRT-D versus ICD therapy and
explore the factors associated with the more favorable
response to this therapy in women than in men.
Methods
Trial design. The design and primary results of the
MADIT-CRT trial were recently published (2). Briefly,
the MADIT-CRT study was designed to determine
whether CRT-D therapy would reduce the risk of deathor heart failure events in patients with mild cardiac
symptoms, a reduced ejection fraction, and wide QRS
complex when compared to ICD therapy. The patients
were randomly assigned in a 3:2 ratio to receive either
CRT-D or ICD. From December 22, 2004, through
April 23, 2008, a total of 1,820 patients were enrolled at
110 hospital centers. Primary analyses included Cox
proportional-hazards regression for heart failure alone
and for death at any time and evaluation of 10 prespeci-
fied categorical subgroups and treatment interactions.
The effects of CRT-D in 7 of these subgroups were
See page 829
presented in the primary analysis of the MADIT-CRT
trial (age, sex, NYHA functional class and substrate,
QRS duration, LVEF, left ventricular end-diastolic vol-
ume, and left ventricular end-systolic volume) and 2
interaction effects between subgroup and treatment were
identified. The CRT-D therapy was associated with a
greater benefit in women than in men, and in patients
with QRS duration 150 than 150 ms.
The protocol was approved by the institutional review
board at each of the participating centers. Patients of
either sex who were at least 21 years of age were enrolled
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February 15, 2011:813–20 Cardiac Resynchronization in Womenin the study if they had ischemic cardiomyopathy
(NYHA functional class I or II) or nonischemic cardio-
myopathy (NYHA functional class II only), sinus
rhythm, an ejection fraction of 0.30, and prolonged
ntraventricular conduction with a QRS duration of
130 ms. All eligible subjects met the guideline indication
Patient Characteristics by SexTable 1 Patient Characteristics by Sex
Women
(n  453)
Men
(n  1,367)
Age, yrs 64 11 65 11
Race
White* 86 92
Black* 12 6
Other 2 2
Cardiac history
Ischemic heart disease
NYHA functional class I*
5 18
Ischemic heart disease
NYHA functional class II*
23 46
Nonischemic heart disease
NYHA functional class II*
72 36
NYHA functional class III or IV 3 months
before enrollment
10 10
Treatment for hypertension 64 63
Atrial fibrillation 1 month before
enrollment*
7 13
Diabetes mellitus 31 30
Cigarette smoking* 9 13
Body mass index 30 kg/m2 34 37
Coronary artery bypass surgery* 12 35
Cardiac findings at enrollment
Systolic blood pressure, mm Hg 122 18 123 17
Diastolic blood pressure, mm Hg* 71 11 72 11
Blood urea nitrogen 25 mg/dl* 19 26
Creatinine 1.4 mg/dl* 9 26
Left bundle branch block* 87 65
Right bundle branch block* 4 15
QRS duration, ms 158 17 158 20
QRS duration 150 ms 67 64
Left ventricular ejection fraction* 0.23 0.05 0.24 0.05
6-min walk distance, m* 328 107 371 105
Echocardiogram/Doppler, baseline
LVEDV index, ml/m2 122 27 124 29
LVESV index, ml/m2 87 21 89 24
LAV index, ml/BSA 46 10 47 10
Medications at baseline
Aldosterone antagonist 36 30
Amiodarone* 3 9
Angiotensin-converting enzyme inhibitors* 72 79
Angiotensin-receptor blockers* 26 19
Beta-blockers* 97 92
Digitalis* 36 22
Diuretics* 75 68
Lipid-lowering statin drugs* 53 72
Values are mean  SD or %. *Indicates p  0.01.
BSA  body surface area; LAV  left atrial volume; LVEDV  left ventricular end-diastolicolume; LVEF  left ventricular ejection fraction; LVESV  left ventricular end-systolic volume;
YHA  New York Heart Association.for ICD therapy. Patients were
excluded from enrollment for a
variety of reasons as previously
reported (2).
Echocardiographic studies. Two-
dimensional echocardiography (3)
was performed at baseline and at
the 1-year follow-up in 1,417 pa-
tients to assess changes in the left
ventricular volumes, left atrial vol-
ume, and ejection fraction in the 2
treatment groups. Volumes were
estimated by averaging those de-
rived from the 2- and 4-chamber
views according to Simpson’s method, and the ejection fraction
was calculated using a standardized protocol. Volumes were
indexed for body surface area.
Statistical analysis. For categorical variables, the chi-
square statistic was used to assess group differences. For
continuous variables, comparisons were performed using the
t test for independent samples. Cumulative survival curves
were determined by Kaplan-Meier analysis (4), with statis-
tical comparison by the log-rank method. The Cox
proportional-hazards regression model (5) was used to
calculate the risk for specified end points, and selective
treatment interactions were evaluated. Outcome analyses
were performed according to the intention-to-treat princi-
ple. The Wilcoxon rank-sum test was used to evaluate the
absolute change in the median difference in echocardio-
graphic parameters between female and male patients who
had paired baseline and 12-month recordings. All p values
are 2-tailed and have not been adjusted for the stopping
rule. Analyses used version 3.0 of the database, which was
released on September 30, 2009.
Results
Clinical characteristics. The clinical characteristics of 453
women and the 1,367 men are presented in Table 1. The
female patients were more likely to have nonischemic
cardiomyopathy and left bundle branch block conduction
pattern than male patients, whereas men were more likely to
have ischemic heart disease, prior coronary revasculariza-
tion, and renal dysfunction than women. The patients were
well treated with appropriate cardiac medications, but there
were some significant differences in medication utilization
between women and men (Table 1).
End point analyses. The primary end point of heart failure
or death (whichever came first) occurred in 376 patients: 29
of 275 (11%) in women with CRT-D, 51 of 178 (29%) in
women with ICD, 159 of 814 (20%) in men with CRT-D,
and 137 of 553 (25%) in men with ICD. These end points
included 54 deaths and 322 heart failure events. Kaplan-
Meier estimates of the probability of the primary end
Abbreviations
and Acronyms
CRT-D  cardiac
resynchronization therapy
with defibrillator
ICD  implanted
cardioverter-defibrillator
LBBB  left bundle branch
block
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Associationpoint in women and men with CRT-D and ICD therapy
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Cardiac Resynchronization in Women February 15, 2011:813–20are shown in Figure 1. Overall, women receiving CRT-D
therapy had a significantly better outcome than women
receiving ICD therapy and men receiving ICD or
CRT-D therapy during an average follow-up duration of
2.4 years.
The hazard ratios for CRT-D to ICD therapy in women
and men for heart failure or death (whichever came first),
heart failure only, or death at any time in the overall study
population as well as by disease etiology, QRS duration,
and left bundle branch block (LBBB) conduction distur-
bance are presented in Table 2. For all 3 outcomes,
women achieved better results from CRT-D therapy than
men, with significant differences between the sexes (in-
teraction p  0.05) for all 3 outcomes in the total
opulation and for 2 of the 3 outcomes in those with
onischemic cardiomyopathy, QRS 150 ms, and LBBB
Table 2). The CRT-D therapy was associated with
ignificantly reduced mortality in women (p  0.02) but
ot in men in the total population (Table 2 and Fig. 2),
n women with QRS 150 ms, and in women with
BBB conduction disturbance (Table 2). In these 3 mor-
ality analyses, the sex-by-treatment interactions were sig-
ificant at p  0.05 (Table 2).
We explored for treatment interactions in prespecified
ex-related subgroups. In patients with nonischemic cardio-
yopathy and QRS 150 ms, the hazard ratio for heart
ailure or death was 0.28 (p  0.001) for women and 0.72
p 0.28) for men, with a significant p 0.047 interaction.
n patients with nonischemic cardiomyopathy and LBBB,
he hazard ratio for heart failure or death was 0.22 (p 
.001) for women and 0.73 (p  0.24) for men, with a
Figure 1
Kaplan-Meier Estimates of Cumulative Probability of
Heart Failure or Death Stratified by Sex and ICD or
CRT-D Therapy
The 4 curves reflect the probability of heart failure or death, whichever comes
first, over time in women and men having the device therapy—implanted car-
dioverter-defibrillator (ICD) or cardiac resynchronization therapy with defibrillator
(CRT-D)—to which they were randomized. Women randomly assigned to CRT-D
therapy (blue line) had the best result. The purple line indicates female ICD
therapy; the black line indicates male ICD therapy; and the red line indicates
male CRT-D therapy.ignificant p  0.005 interaction. The interaction analyses sor the end point of death in these at-risk subgroups were
ot significant.
chocardiographic findings. The changes in echocardio-
raphic volumes and ejection fraction parameters between
aseline and 1-year follow-up for women and men in the
otal population and by disease etiology, QRS duration, and
BBB are presented in Table 3. All echocardiography
arameters improved to a significantly greater degree with
RT-D therapy than with ICD therapy within both the
emale group and the male group (p  0.001). Women had
onsistently greater improvements in reverse cardiac remod-
ling with CRT-D therapy than did men, with the most
ignificant differences evident in the total population and in
atients with QRS 150 ms or LBBB (Table 3).
dverse events. Adverse events were more frequent among
he CRT-D–treated patients (11%) than in the ICD-
reated patients (4.5%). Women had an overall higher
ikelihood of all device-related adverse events than men,
0.5% versus 7.9%, respectively (p  0.001). Women were
ore likely to have pneumothorax (3% in women vs. 0.73%
n men), but men were more likely to have lead dislodge-
ent (1.7% in women vs. 3.2% in men).
iscussion
n this substudy from the MADIT-CRT trial, 25% of the
tudy population was female. Although men received sig-
ificant benefit from CRT-D therapy, women had signifi-
antly better results with CRT-D therapy than men for
eath or heart failure (whichever came first), for heart failure
nly, and for death at any time. Women had a significant
2% reduction in all-cause mortality in the total population,
ith even greater reductions in mortality for those with
RS 150 ms or with LBBB, with significant sex-by-
reatment interactions in the 3 patient groups for the
ortality end point.
There were significant differences in baseline character-
stics between women and men that could have contributed
n part to the observed findings. A greater proportion of the
emale cohort had a substrate of nonischemic cardiomyop-
thy and an underlying LBBB pattern, but the percentage of
atients with QRS 150 ms and the mean QRS durations
ere not significantly different between women and men.
omen had a higher utilization of beta-blockers than men.
en had a greater proportion of ischemic cardiomyopathy
nd a history of atrial fibrillation and renal dysfunction
ompared with women. The latter 2 clinical characteristics
ave been associated with poor prognosis and higher risk of
eath in the MADIT-2 study population (6). A higher
roportion of men had a right bundle branch block pattern,
nd an association between the presence of right bundle branch
lock and poor outcome with CRT has been noted (7).
In heart failure studies, women, especially those with
onischemic heart disease, have been shown to have an
verall survival advantage (8), and other groups have
hown that women achieve greater reduction in left
817JACC Vol. 57, No. 7, 2011 Arshad et al.
February 15, 2011:813–20 Cardiac Resynchronization in WomenRisk of Death or Heart Failure by SexTable 2 Risk of Death or Heart Failure by Sex
Study Group End Points
CRT-D:ICD Hazard Ratio* (p Value),
Interaction p Value
95% Confidence Interval
Women Men
Total population (453, 1,365)
Death or heart failure (80, 296) 0.31 (0.001) 0.72 (0.01) 0.01
0.19–0.50 0.57–0.92
Heart failure only (73, 249) 0.30 (0.001) 0.65 (0.001) 0.01
0.18–0.50 0.50–0.84
Death at any time (20, 107) 0.28 (0.02) 1.05 (0.83) 0.03
0.10–0.79 0.70–1.57
Disease etiology
Ischemic heart disease (125, 874)
Death or heart failure (25, 216) 0.32 (0.01) 0.65 (0.01) NS
0.13–0.78 0.49–0.86
Heart failure only (23, 180) 0.31 (0.01) 0.58 (0.001) NS
0.12–0.76 0.43–0.79
Death at any time (5, 83) 0.17 (0.13) 0.99 (0.95) NS
0.02–1.66 0.62–1.57
Nonischemic heart disease (328, 493)
Death or heart failure (55, 80) 0.30 (0.001) 0.96 (0.86) 0.01
0.17–0.54 0.60–1.53
Heart failure only (50, 69) 0.31 (0.001) 0.88 (0.62) 0.01
0.17–0.56 0.54–1.45
Death at any time (15, 24) 0.33 (0.07) 1.34 (0.52) NS
0.10–1.10 0.55–3.31
QRS duration
QRS 150 ms (148, 497)
Death or heart failure (25, 122) 0.30 (0.01) 1.09 (0.66) 0.01
0.12–0.73 0.74–1.60
Heart failure only (23, 107) 0.26 (0.01) 1.08 (0.72) 0.01
0.10–0.65) 0.71–1.60
Death at any time (8, 42) 0.40 (0.23) 1.20 (0.59) NS
0.09–1.80 0.62–2.34
QRS 150 ms (305, 870)
Death or heart failure (55, 174) 0.30 (0.001) 0.55 (0.001) NS
0.17–0.54 0.40–0.75
Heart failure only (50, 142) 0.31 (0.001) 0.45 (0.001) NS
0.17–0.58 0.32–0.64
Death at any time (12, 65) 0.18 (0.05) 1.03 (0.90) 0.05
0.04–0.89 0.61–1.75
Conduction disturbance
Non-LBBB (59, 478)
Death or heart failure (11, 111) 1.97 (0.40) 1.15 (0.51) NS
0.40–9.64 0.76–1.76
Heart failure only (10, 96) 1.95 (0.41) 1.04 (0.88) NS
0.40–9.53 0.67–1.61
Death at any time — — —
LBBB (394, 887)
Death or heart failure (69, 185) 0.23 (0.01) 0.53 (0.01) 0.01
0.13–0.40 0.39–0.72
Heart failure only (63, 153) 0.22 (0.01) 0.47 (0.01) 0.03
0.12–0.40 0.34–0.66
Death at any time (17, 68) 0.22 (0.01) 0.84 (0.50) 0.04
0.07–0.70 0.67–1.61
Numbers in parentheses represent patient counts (female, male) in the header rows and event counts in rows with event types. In the non–left bundle
branch block (LBBB) group, the Cox regression model for death at any time was unstable owing to a paucity of death events, so hazard ratios are not
provided. *Adjusted for history of atrial arrhythmias, ischemic status and New York Heart Association functional class, race, creatinine, left ventricular
ejection fraction, distance walked in 6-min test, and left atrial volume. Medications did not make a significant contribution to the analyses.
CRT-D  cardiac resynchronization therapy with defibrillator; ICD  implantable cardioverter-defibrillator; NS  not significant (p  0.05).
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after CRT therapy (9). No prior study has demonstrated
a significantly greater benefit from device therapy for
women than men regarding mortality or cardiac-related
outcomes in an overall study population or by disease
etiology. In the current MADIT-CRT analysis, CRT-
D:ICD hazard ratios were significantly better for women
than for men for all 3 end points in the total population
and for 2 of the 3 end points in those with nonischemic
cardiomyopathy (see sex-by-treatment interaction p val-
ues in Table 2). Women with nonischemic cardiomyop-
athy were uniquely responsive to CRT relative to men,
and the reason for this sex-related beneficial effect is
unclear. It is possible that among patients with heart
disease, the risk of heart failure is greater for women than
for men, resulting in a greater benefit from preventive
CRT-D therapy in women.
It is generally appreciated that in subjects without heart
disease, women have, on average, approximately 10 ms
shorter QRS durations than men (10). In subjects with
heart failure, prolongation of QRS 120 ms occurs in 14%
to 47% of patients overall (11). In the MADIT-CRT trial,
we used the same entry criteria of QRS 130 ms for both
women and men. Thus, for any given QRS duration
Figure 2 Kaplan-Meier Estimates of the Cumulative Probability
of Death in Women and Men by Device Therapy
(A) Women had a significantly lower probability of death over time with CRT-D
(red line) than with ICD (black line). (B) Men had similar probability of death
over time with CRT-D therapy (red line) or with ICD therapy (black line). Abbre-
viations as in Figure 1.130 ms, women might have, on a relative basis, moreconduction disturbance and greater cardiac dyssynchrony
than men, and this might explain why women were more
responsive to cardiac resynchronization therapy than men
in this trial. It is interesting that LBBB was present in
70% of the MADIT-CRT patients and in 87% of female
patients. Although both sexes with LBBB benefited from
CRT-D therapy, women with LBBB achieved a signifi-
cantly better result with this therapy than did men with
LBBB (Table 2).
Several major CRT trials involved patients with NYHA
functional class III and IV heart failure (9,12–14). In the
MIRACLE (Multicenter InSync Randomized Clinical
Evaluation) study (14), 32% of the study group were
women; and among women receiving CRT, there was a
reduction in heart failure hospitalization or death com-
pared with the control group (hazard ratio: 0.157, p 
.002). No differences were seen among men for either
nd point with CRT, even when accounting for baseline
emographics and heart failure etiology (14). In the
OMPANION (Comparison of Medical Therapy, Pac-
ng, and Defibrillation in Heart Failure) trial, women
ade up 33% of the study population, and these patients
ad a 56% reduction in the risk of sudden cardiac death
ith CRT-D compared with optimal pharmacologic
herapy, with female sex associated with reduced risk in
onjunction with CRT-D therapy (hazard ratio: 0.56, p 
.003) (9). When CRT or CRT-D therapy was compared
to optimal pharmacologic therapy in COMPANION,
these therapies were similarly beneficial in reducing mortal-
ity in women and men, and there were no significant
sex-by-treatment interactions (15). In the CARE-HF (Car-
diac Resynchronization in Heart Failure) study, about 25%
of the study group were women, but the CRT to medical
therapy hazard ratios for women and men for the primary
end point (death or hospitalization) were similar, in the 0.62
to 0.64 range (12). In the recently reported European cohort
of the REVERSE (Resynchronization Reverses Remodel-
ing in Systolic Left Ventricular Dysfunction) trial involving
162 patients with NYHA functional class I and II heart
failure, LVEF 0.35, and QRS 120 ms, approximately
20% of the subjects were female, and the clinical composite
end point of worsened heart failure was reduced to a similar
degree with CRT therapy in women and men (16). This
REVERSE trial had higher LVEF and less prolonged QRS
duration criteria for enrollment than the MADIT-CRT
study did, and there was limited power to find sex differ-
ences in outcome in view of the small number of patients in
the trial.
Conclusions
Women in the MADIT-CRT trial obtained significantly
greater reductions in death or heart failure (whichever came
first), heart failure alone, and all-cause mortality with
Cf
819JACC Vol. 57, No. 7, 2011 Arshad et al.
February 15, 2011:813–20 Cardiac Resynchronization in WomenCRT-D therapy than men. These more favorable results for
women were associated with consistently greater echocar-
diographic evidence of reverse cardiac remodeling in women
than in men.
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